Molecular Partners AG (XSWX:MOLN) ROCE %: -61.84% (As of Mar. 2026)


XSWX:MOLN Molecular Partners AG XSWX:MOLN
29 GF Score
Price CHF3.12
GF Value CHF0.37
Valuation Significantly Overvalued
! 3 Warning Signs
View Full Analysis

What is Molecular Partners AG ROCE %?

Molecular Partners AG XSWX:MOLN +0.65% 29 ROCE % is -61.84% as of Mar. 2026. GuruFocus rates XSWX:MOLN with a GF Score™ of 29/100 and a GF Value™ of CHF0.37 (Significantly Overvalued). The stock has 3 warning signs investors should review.

ROCE % measures how well a company generates profits from its capital. It is calculated as EBIT divided by Capital Employed, where Capital Employed is calculated as Total Assets minus Total Current Liabilities. Molecular Partners AG's annualized ROCE % for the quarter that ended in Mar. 2026 was -61.84%.

Molecular Partners AG  (XSWX:MOLN) ROCE % Explanation

ROCE % can be especially useful when comparing the performance of capital-intensive companies. Unlike ROE %, which indicates the profitability of Shareholders Equity, ROCE % also considers long-term debt in Capital Employed. This can be helpful when analyzing companies with significant debt, as the result is neutralized by taking debt into consideration.

Generally speaking, a higher ROCE % indicates a stonger profitability for a company. Moreover, it is important to look at the ratio from a long term perspective. Investors tend to favor companies with stable and rising ROCE % trend over those with volatile ones.

Molecular Partners AG ROCE % Related Terms

Molecular Partners AG ROCE % Historical Data

* Premium members only.

The historical data trend for Molecular Partners AG's ROCE % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Molecular Partners AG ROCE % Chart

Molecular Partners AG Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
ROCE %
Get a 7-Day Free Trial Premium Member Only Premium Member Only -49.46 63.89 -28.88 -32.57 -51.61

Molecular Partners AG Quarterly Data
Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26
ROCE % Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -47.93 -67.01 -44.70 -52.80 -61.84
XSWX:MOLN
29GF Score
Molecular Partners AG XSWX:MOLN
ROCE % is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Molecular Partners AG ROCE % Calculation

Molecular Partners AG's annualized ROCE % for the fiscal year that ended in Dec. 2025 is calculated as:

ROCE %=EBIT/( (Capital Employed+Capital Employed)/ count )
(A: Dec. 2025 )  (A: Dec. 2024 )(A: Dec. 2025 )
=EBIT/( ( (Total Assets - Total Current Liabilities)+(Total Assets - Total Current Liabilities) )/ count )
(A: Dec. 2025 )  (A: Dec. 2024 )(A: Dec. 2025 )
=-61.631/( ( (158.528 - 10.785) + (102.107 - 11.027) )/ 2 )
=-61.631/( (147.743+91.08)/ 2 )
=-61.631/119.4115
=-51.61 %

Molecular Partners AG's ROCE % of for the quarter that ended in Mar. 2026 is calculated as:

ROCE %=EBIT (1)/( (Capital Employed+Capital Employed)/ count )
(Q: Mar. 2026 )  (Q: Dec. 2025 )(Q: Mar. 2026 )
=EBIT/( ( (Total Assets - Total Current Liabilities)+(Total Assets - Total Current Liabilities) )/ count )
(Q: Mar. 2026 )  (Q: Dec. 2025 )(Q: Mar. 2026 )
=-52.548/( ( (102.107 - 11.027) + (87.658 - 8.799) )/ 2 )
=-52.548/( ( 91.08 + 78.859 )/ 2 )
=-52.548/84.9695
=-61.84 %

(1) Note: The EBIT data used here is four times the quarterly (Mar. 2026) EBIT data.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Frequently Asked Questions Learn more about ROCE % →
What does a ROCE % of -61.84% mean?
Molecular Partners AG (XSWX:MOLN) has a ROCE % of -61.84% as of Mar. 2026.
Is Molecular Partners AG's ROCE % too high?
Molecular Partners AG's current ROCE % is -61.84%. Overall, Molecular Partners AG has a GF Score™ of 29/100 and is considered Significantly Overvalued, reflecting its overall financial health beyond just this single metric.
How does Molecular Partners AG's ROCE % compare to VRTX and REGN?
Molecular Partners AG's ROCE % of -61.84% can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good ROCE % for a Biotechnology company?
A good ROCE % depends on the Biotechnology industry context. However, ROCE % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high ROCE % mean?
A high ROCE % can signal that a stock is expensive relative to its fundamentals. Molecular Partners AG's current ROCE % is -61.84%. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Molecular Partners AG stock overvalued right now?
Based on GuruFocus' analysis, Molecular Partners AG (XSWX:MOLN) is currently considered Significantly Overvalued. The stock's GF Value™ is CHF0.37, compared to a current price of CHF3.12 — trading 743.2% above its estimated fair value. The current ROCE % is -61.84%. Molecular Partners AG's overall GF Score™ is 29/100 with 3 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is ROCE % calculated?
ROCE % is calculated from a company's financial statements. For Molecular Partners AG (XSWX:MOLN), the current ROCE % is -61.84% as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Molecular Partners AG (XSWX:MOLN) Overvalued in 2026?

Based on GuruFocus' analysis, Molecular Partners AG stock appears to be overvalued. The current stock price of CHF3.12 is trading 743.2% above its estimated GF Value™ of CHF0.37. GuruFocus considers Molecular Partners AG to be Significantly Overvalued.

Key valuation signals for XSWX:MOLN:

  • ROCE %: -61.84%
  • GF Value™: CHF0.37 vs. price of CHF3.12 (743.2% above fair value)
  • GF Score™: 29/100 with 3 warning signs

No single metric tells the full story. See the XSWX:MOLN stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

Molecular Partners AG Business Description

Address Wagistrasse 14, Schlieren, Zurich, CHE, 8952
Molecular Partners AG is a clinical stage biopharmaceutical company. The Company has programs in various stages of pre-clinical and clinical development, with oncology as its main focus. The firm develops protein therapeutics called DARPin therapeutics for the treatment of serious diseases, including cancer and sight-threatening disorders. The company is currently focusing on oncology through their robust pipeline of clinical and preclinical programs, with particular attention to MP0712, the key Radio-DARPin candidate targeting DLL3 now in a Phase 1/2a trial in the United States.
29GF Score

Get the complete analysis for XSWX:MOLN

ROCE % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

CHF3.12
Price
CHF0.37
GF Value